Literature DB >> 22806148

[Pulmonary allergic reactions].

A R Koczulla1, B Beutel, T Greulich, A Jerrentrup, C Vogelmeier.   

Abstract

Allergic diseases of the lungs may affect the airways, the pulmonary parenchyma and the pulmonary vessels. The most relevant representatives are allergic asthma, hypersensitivity pneumonitis, bronchopulmonary aspergillosis and the Churg-Strauss syndrome. The type of allergic reaction and the pathophysiological consequences vary considerably between these entities. New drugs target specific mechanisms based on new insights into the pathogenetic processes of the underlying disease.

Entities:  

Mesh:

Year:  2012        PMID: 22806148     DOI: 10.1007/s00108-012-3059-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  73 in total

1.  Symposium on the definition and management of anaphylaxis: summary report.

Authors:  Hugh A Sampson; Anne Muñoz-Furlong; S Allan Bock; Cara Schmitt; Robert Bass; Badrul A Chowdhury; Wyatt W Decker; Terence J Furlong; Stephen J Galli; David B Golden; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Marilyn Howarth; Allen P Kaplan; Jerrold H Levy; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Ramon Murphy; Susan M Pollart; Richard S Pumphrey; Lanny J Rosenwasser; F Estelle Simons; Joseph P Wood; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

2.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

Review 3.  Allergic bronchopulmonary aspergillosis and fungoses.

Authors:  P A Greenberger
Journal:  Clin Chest Med       Date:  1988-12       Impact factor: 2.878

Review 4.  Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Authors:  Gustavo J Rodrigo; Hugo Neffen; José A Castro-Rodriguez
Journal:  Chest       Date:  2010-08-05       Impact factor: 9.410

Review 5.  Cytokines and airway inflammation.

Authors:  P H Howarth; P Bradding; D Quint; A E Redington; S T Holgate
Journal:  Ann N Y Acad Sci       Date:  1994-05-28       Impact factor: 5.691

Review 6.  A new look at hypersensitivity pneumonitis.

Authors:  M Ando; M Suga; H Kohrogi
Journal:  Curr Opin Pulm Med       Date:  1999-09       Impact factor: 3.155

7.  CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome.

Authors:  Tomáš Dallos; Gisela Ruiz Heiland; Johanna Strehl; Thomas Karonitsch; Wolfgang L Gross; Frank Moosig; Constanze Holl-Ulrich; Jörg H W Distler; Bernhard Manger; Georg Schett; Jochen Zwerina
Journal:  Arthritis Rheum       Date:  2010-11

Review 8.  Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models.

Authors:  Maggie J Leckie
Journal:  Am J Respir Med       Date:  2003

9.  Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

Authors:  Adaobi Kanu; Kalpana Patel
Journal:  Pediatr Pulmonol       Date:  2008-12

Review 10.  The epithelium takes centre stage in asthma and atopic dermatitis.

Authors:  Stephen T Holgate
Journal:  Trends Immunol       Date:  2007-04-27       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.